Estrace (Estradiol Vaginal) - Adverse Event Reports - Hospitalization - Breast Cancer

Adverse event in 62 year old female receiving Estrace (Estradiol Vaginal)

Reported by a individual with unspecified qualification from United States on 2007-07-02

Patient: 62 year old female, weighing 99.8 kg (219.5 pounds)

Adverse reactions / side effects: Polyp Colorectal, Mammogram Abnormal, Fibrocystic Breast Disease, Intervertebral Disc Disorder, Postmenopausal Haemorrhage, Breast Microcalcification, Blood Cholesterol Increased, Benign Breast Neoplasm, Breast Hyperplasia, Breast Cancer, Tonsillectomy, Abscess Drainage, Mastitis, Radiotherapy, Malignant Breast Lump Removal, Appendicitis, Anal Fissure, Haematochezia, Hysterectomy, Uterine Dilation and Curettage, Colonoscopy Abnormal

Adverse event resulted in: hospitalization

Suspect drug(s):
Cycrin
    Start date: 1999-01-01

Estrace
    Dosage: unk, qhs
    Start date: 1999-01-01

Estraderm
    Start date: 1989-01-01

Estratest
    Start date: 1990-01-01
    End date: 1999-01-01

Premarin
    Dosage: 0.625 unk, unk
    Administration route: Oral
    Start date: 1989-01-01

Prempro
    Indication: Menopause
    Start date: 1999-04-01
    End date: 2002-04-01

Provera
    Dosage: 10 mg, unk
    Start date: 1989-01-01

Other drugs received by patient: Steroids NOS; Oxygen Therapy; Lotrel; Cardizem

Adverse event in 61 year old female receiving Estrace (Estradiol Vaginal)

Reported by a individual with unspecified qualification from United States on 2007-03-28

Patient: 61 year old female, weighing 89.8 kg (197.5 pounds)

Adverse reactions / side effects: Breast Cancer, Biopsy Breast Abnormal, Breast Mass, Malignant Breast Lump Removal, Progesterone Receptor Assay Positive, Haemangioma of Liver, Limb Discomfort, Oedema Peripheral, Depression, Lymphadenectomy, Knee Arthroplasty, Oestrogen Receptor Assay Positive, Lung Infiltration

Adverse event resulted in: hospitalization

Suspect drug(s):
Estrace
    Indication: Night Sweats

Estratab
    Dosage: 0.625 mg, qd
    Indication: Night Sweats

Estropipate
    Dosage: 1 mg, unk
    Indication: Amnesia

Premarin
    Dosage: 0.625 mg, unk
    Indication: Affective Disorder

Prempro
    Indication: Amnesia

Provera
    Dosage: 2.5 mg, qd
    Indication: Hormone Replacement Therapy

Vivelle
    Indication: Hormone Replacement Therapy

Vivelle-DOT
    Indication: Hormone Replacement Therapy

Other drugs received by patient: Fish OIL; Alprazolam; Celebrex

Adverse event in 59 year old female receiving Estrace (Estradiol Vaginal)

Reported by a individual with unspecified qualification from United States on 2007-03-27

Patient: 59 year old female, weighing 96.1 kg (211.5 pounds)

Adverse reactions / side effects: Abdominal Pain, Abdominal Operation, Urinary Incontinence, Cervix Disorder, Incisional Hernia, Upper Respiratory Tract Infection, Central Venous Catheterisation, Postmenopausal Haemorrhage, Colostomy, Tendonitis, Rectal Prolapse, Breast Cancer, Enterostomy, Pelvic Abscess, Bursitis, non-Cardiac Chest Pain, Menopause, Cholelithiasis, Emotional Distress, Diverticulum, Vaginal Infection, Uterine Haemorrhage, Oophorectomy, Bladder Prolapse, Post Procedural Complication, Pain, Pelvic Pain, Cardiac Valve Disease, Hypercholesterolaemia, Ovarian Cystectomy, Fibrocystic Breast Disease, Basal Cell Carcinoma, Haemorrhagic Ovarian Cyst, Injury, Renal Failure Acute, Cataract, Mass, Urinary Tract Infection, Synovitis, Hernia, Tubal Ligation, Osteoarthritis, Adhesiolysis, Small Intestinal Resection, Radical Mastectomy, Uterine Prolapse Repair, Hypertension, Leukopenia, Abdominal Adhesions

Adverse event resulted in: hospitalization

Suspect drug(s):
Estrace
    Dosage: 1 mg, qd
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1994-05-23

Estrace Vaginal Cream
    Dosage: 2 g oncde per week
    Indication: Menopausal Symptoms
    Start date: 1994-04-27

Estrace Vaginal Cream
    Dosage: 2 g once per week
    Start date: 1994-05-23

Estraderm
    Dosage: 0.1 mg, unk
    Start date: 1999-08-02

Loestrin 1.5 / 30
    Dosage: 1.5 mg, unk
    Start date: 1994-09-08

Premarin
    Dosage: 0.625 mg, qd
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 1984-09-26
    End date: 1997-10-01

Prempro
    Dosage: .625/5 mg
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 1997-06-25
    End date: 2001-12-02

Provera
    Dosage: 2.5 mg, qd
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 1994-05-23

Provera
    Dosage: 5 mg, qd
    Administration route: Oral
    Start date: 1996-01-02
    End date: 1997-10-01

Other drugs received by patient: Prilosec; Avalide

Adverse event in 57 year old female receiving Estrace (Estradiol Vaginal)

Reported by a individual with unspecified qualification from United States on 2007-03-01

Patient: 57 year old female, weighing 56.7 kg (124.7 pounds)

Adverse reactions / side effects: Breast Cancer, Back Pain, Pain in Extremity, Angina Pectoris, Osteoporosis, Musculoskeletal Pain, Tachycardia, Radiotherapy, Lumbar Radiculopathy, Cervical Conisation, Smear Cervix Abnormal, Catheterisation Cardiac, Palpitations, Intervertebral Disc Disorder, Mastectomy, Spinal Osteoarthritis, Gastrooesophageal Reflux Disease

Adverse event resulted in: hospitalization

Suspect drug(s):
Estrace
    Indication: Hormone Replacement Therapy
    Start date: 1993-08-12
    End date: 1993-09-14

Estraderm
    Dosage: 0.05 mg patch
    Indication: Hormone Replacement Therapy
    Start date: 1993-09-14
    End date: 1994-08-08

Premarin
    Dosage: 0.3-0.625mg
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1989-06-06
    End date: 1993-08-12

Provera
    Dosage: 2.5-10mg
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1989-06-06
    End date: 1994-09-14

Other drugs received by patient: Maxzide; Atenolol; Norethindrone; Tamoxifen Citrate